Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment

Inhibition of the PD-1/PD-L1 pathway is a target for the development of new therapies. US10710986 patent describes a small molecule that targets PDL-1/PD-1 interactions and triggers antitumor activity against colorectal cancer. However, it does not describe biological assays that allow us to suppose...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical patent analyst 2021-12, Vol.10 (6), p.245-250
Main Authors: Anaya-Ruiz, Maricruz, Perez-Santos, Martin
Format: Article
Language:English
Subjects:
cancer
immunotherapy
PD-1
PD-L1
small molecule
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inhibition of the PD-1/PD-L1 pathway is a target for the development of new therapies. US10710986 patent describes a small molecule that targets PDL-1/PD-1 interactions and triggers antitumor activity against colorectal cancer. However, it does not describe biological assays that allow us to suppose that this small molecule may be active in other types of cancer. So far, there are no reports of clinical trials to evaluate the safety, toxicity and efficacy, but it will be of great interest to analyze in the future if this compound surpasses the action of therapy in cancer.
ISSN:2046-8954
2046-8962
DOI:10.4155/ppa-2021-0016